Nuveen
ADCT icon

Nuveen’s ADC Therapeutics ADCT Stock Holding History

Nuveen’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$189K Buy
176,693
+30,435
+21% +$88.8K ﹤0.01% 3653
2026
Q1 		$548K Buy
146,258
+27,343
+23% +$108K ﹤0.01% 2805
2025
Q4 		$420K Sell
118,915
-52,315
-31% -$212K ﹤0.01% 2939
2025
Q3 		$685K Buy
171,230
+52,315
+44% +$165K ﹤0.01% 2781
2025
Q2 		$319K Sell
118,915
-33,132
-22% -$69.7K ﹤0.01% 3027
2025
Q1 		$214K Hold
152,047
– – ﹤0.01% 3122
2024
Q4 		$303K Buy
152,047
+22,989
+18% +$60.2K ﹤0.01% 3128
2024
Q3 		$407K Sell
129,058
-108,246
-46% -$341K ﹤0.01% 3078
2024
Q2 		$750K Buy
+237,304
New +$943K ﹤0.01% 2850

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Nuveen's ADCT Position: Q2 2026 in Review

Nuveen increased its ADC Therapeutics (ADCT) stake by 21% in Q2 2026, buying an estimated $88.8K and bringing the position to 176,693 shares worth $189K. The position accounts for ﹤0.01% of the portfolio, ranked #3653.

Nuveen first reported a position in ADCT in Q2 2024 and has held it in 9 quarters since. The position peaked at $750K in Q2 2024. 113 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Nuveen held 176,693 shares of ADC Therapeutics worth $189K as of Q2 2026.
  • Nuveen bought 30,435 ADC Therapeutics shares in Q2 2026, an estimated $88.8K.
  • ADC Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3653 holding.
  • Nuveen first reported a position in ADC Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Nuveen's ADC Therapeutics position peaked at $750K in Q2 2024.
  • 113 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.